---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-24-000093"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2024-09-20T23:59:59+00:00"
generated_at: "2026-05-31T02:41:54.784988+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ANI Pharma closes Alimera Sciences acquisition; $5.50/sh cash plus CVRs

## Summary
- Acquisition closed Sept 16, 2024; Alimera shareholders received $5.50 cash per share plus one CVR per share.
- CVRs tied to net revenue of ILUVIEN and YUTIQ: $140M by FY2026, $160M by FY2027; max payout $0.25 per CVR per milestone.
- Financed with $325M senior secured term loan from JPMorgan-led syndicate plus available cash.
- Pro forma results show combined net loss of $3.4M for H1 2024 and $51.6M for FY2023.
- Audited Alimera financials and unaudited pro forma combined statements filed as Exhibits 99.1-99.3.

## SEC filing metadata
- accession: 0001023024-24-000093
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2024-09-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000093/0001023024-24-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000093/ani-20240916.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-24-000093
- JSON: https://secwatch.observer/filing/0001023024-24-000093.json
- Plain text: https://secwatch.observer/filing/0001023024-24-000093.txt

## Key facts
- M&A Transactions
  ANI PHARMACEUTICALS INC completed an acquisition involving Alimera Sciences, Inc. for $5.50 in cash, without interest and one contingent value right (closed 2024-09-16).
  - Action: acquisition
  - Counterparty: Alimera Sciences, Inc.
  - Consideration: $5.50 in cash, without interest and one contingent value right
  - Closing: 2024-09-16
  source text: or shares owned by the Company, Merger Subs or any other subsidiary of the Company or Alimera), was canceled and ceased to exist and was converted into the right to receive (i) $5.50 in cash, without interest (the “ Closing Cash Consideration ”) and (ii) one contingent value right (a “ CVR ”), which represents the right to receive the Milestone Payments (as
  evidence_url: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000093/0001023024-24-000093-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.